RxDoctor Payments DataLook up a doctor →

Scott Guenthner, MD

Dermatology · Plainfield, INNPI 1396748778

Payments from drug & device makers

$10,651,775in general payments, 2019–2025

Across 4,751 payments — averaging $2242.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2M
  • Janssen Research & Development, LLC$1.4M
  • AbbVie$1.1M
  • UCB SA$1M
  • Pfizer$617K
  • Incyte Corporation$506K
  • plus $4M from 53 others
$128,090in research payments, 2019–2025

Across 54 payments — averaging $2372.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$64K
  • E.r. Squibb & Sons, L.L.C.$27K
  • Glenmark Pharmaceuticals Inc., USA$18K
  • Ichnos Glenmark Innovation Inc$15K
  • Regeneron$1K
  • Sanofi US Services Inc.$1K
  • plus $2K from 3 others

What the payments were for

  • Consulting fees$187,92411%
  • Speaking & faculty fees$1,240,03876%
  • Travel & lodging$170,76210%
  • Food & beverage$41,4633%
  • Education$5340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly62$1,976,954
Janssen Research & Development, LLC232$1,434,833
AbbVie(2 entities)544$1,053,873
UCB SA49$1,044,585
Pfizer206$617,402
Incyte Corporation461$506,185
Sun Pharmaceutical Industries Inc.197$476,754
Amgen(2 entities)46$360,437
Arcutis Biotherapeutics, Inc.233$356,067
Dermavant Sciences, Inc.834$320,840
E.r. Squibb & Sons, L.L.C.52$289,408
Johnson & Johnson262$280,075
Vanda Pharmaceuticals Inc.47$221,633
Biofrontera Inc.27$201,931
Sanofi131$168,495
LEO Pharma AS25$133,611
LEO Pharma Inc.181$132,569
Janssen Scientific Affairs, LLC107$130,429
Galderma Laboratories, L.p.161$122,993
Boehringer Ingelheim21$115,522
Dermira, Inc.34$108,917
Sanofi US Services Inc.100$108,636
Almirall LLC13$80,754
Acrotech Biopharma Inc.17$78,525
Regeneron122$76,566
Journey Medical Corporation25$76,547
Bristol Myers Squibb6$32,772
Taro Pharmaceuticals USA, Inc.4$21,839
VYNE Pharmaceuticals Inc.14$20,532
Parapro, LLC2$18,200
Organon11$15,826
Verrica Pharmaceuticals Inc.18$14,096
Kowa Pharmaceuticals America, Inc.10$13,900
Boehringer Ingelheim Canada Ltd.ltee36$7,826
Lilly USA, LLC68$7,710
Novartis204$4,980
Ortho Dermatologics, A Division Of Bausch Health US, LLC31$3,296
Boehringer Ingelheim Pharma GmbH & Co.kg1$3,156
Aclaris Therapeutics, Inc.8$3,022
Senseonics, Incorporated3$2,532
UCB Biosciences Inc.2$2,179
Merck6$1,772
UCB, Inc.48$1,271
Regeneron Healthcare Solutions, Inc.44$1,002
Vertex1$500
Mayne Pharma Commercial LLC15$239
Strata Skin Sciences, Inc.5$208
EPI Health, LLC3$52
Glenmark Therapeutics Inc.6$52
Sanofi-aventis U.S. LLC1$49
Prugen, Inc. Pharmaceuticals4$43
Genentech USA, Inc.2$33
Midmark Corporation1$26
Encore Dermatology Inc.2$25
Helsinn Therapeutics (U.S.), Inc.2$24
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$23
LNHC, Inc1$20
Botanix SB Inc1$17
Mylan Pharmaceuticals Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,651,775 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$696,626
Medicare patients
1,562
Services billed
9,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib43$369,679
Dupixent PenDupilumab55$219,486
Taltz AutoinjectorIxekizumab15$102,541
Dupixent SyringeDupilumab14$54,614
Clobetasol Propionate248$9,290
Ketoconazole473$6,769
Fluorouracil56$3,628
Triamcinolone Acetonide144$2,335
ValacyclovirValacyclovir Hcl68$2,033
Metronidazole37$1,964
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim87$1,312
Econazole Nitrate34$1,167
Rifampin30$1,095
Doxycycline Hyclate31$997
Betamethasone Dipropionate32$937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,053,873$369,67943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 dermatology providers in Indiana.

Other dermatology in Plainfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →